Actively Recruiting
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies
Led by National Cancer Institute (NCI) · Updated on 2026-03-03
500
Participants Needed
2
Research Sites
666 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Background: RASopathies are a group of conditions caused by a genetic change. People with a RASopathy may have developmental issues, cognitive disability, poor growth, and birth defects. They may also have an increased risk for developing cancer. Researchers want to learn more. Objective: To learn more about RASopathies, how genes and environmental factors contribute to cancer development in people with RASopathies, and the best way to find these cancers and other conditions early or prevent them. Eligibility: People of any age who have or may have a RASopathy, and their family members. Design: Participants will complete questionnaires about their personal and family medical history. Their medical records will be reviewed. Participants will give blood and urine samples. They will give a saliva or cheek cell sample. Some samples will be used for genetic testing. Participants may have a skin biopsy. Participants may have a physical exam by the RASopathies study team. They may also have exams by additional specialists, such as dentists; urologists; ear, nose, and throat doctors; and neurologists. Participants may have computed tomography of the face and mouth. They may have an ultrasound of the abdomen. They may have a bone density scan. They may have skeletal and/or spine x-rays. They may have magnetic resonance imaging of the brain, low back, chest, and/or heart. They may be photographed. Participants may have other tests, such as sleep, brain and heart electrical activity, speech and swallow, metabolism, hearing, eye, and colon function tests. Participants may sign separate consent forms for some tests. Participation will last indefinitely. Participants may be contacted once in a while by phone or mail. They may have follow-up visits.
CONDITIONS
Official Title
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals with a clinical diagnosis of a RASopathy, including Costello syndrome, Noonan syndrome, Noonan syndrome with multiple lentigines, Cardiofaciocutaneous syndrome, Legius syndrome, capillary arteriovenous malformation syndrome, or others
- Individuals with a germline variant in a RASopathy-associated gene, including but not limited to BRAF, CBL, HRAS, KRAS, LZTR1, MAP2K1, MAP2K2, MAP3K8, MRAS, NRAS, PPP1CB, PTPN11, RAF1, RASA1, RASA2, RIT1, RRAS, SHOC2, SOS1, SPRED1
- Individuals with a dual diagnosis of NF1 and another RASopathy
- Family members of carriers, including blood-related relatives without the variant, are eligible as controls
- No age restrictions
- No restrictions related to organ and marrow function
- Prior therapies of any type and amount are allowed
- Informed consent must be signed by the participant or their surrogate
You will not qualify if you...
- Individuals with only neurofibromatosis type 1 (NF1) without another RASopathy
- Individuals who are unable to return for follow-up visits or complete required follow-up studies, as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
National Institutes of Health Clinical Center
Bethesda, Maryland, United States, 20892
Actively Recruiting
2
National Cancer Institute - Shady Grove
Rockville, Maryland, United States, 20850
Actively Recruiting
Research Team
N
NCI Family Study Referrals
CONTACT
D
Douglas R Stewart, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here